SLC6A14-mediated carnitine transmembrane uptake from PPARγ+ cancer-associated fibroblasts promotes recurrence of pancreatic cancer - PubMed
4 days ago
- #Pancreatic Cancer
- #Metabolism
- #Recurrence
- Postoperative recurrence is a major challenge in pancreatic cancer (PC) treatment.
- SLC6A14-mediated carnitine uptake from PPARγ+ cancer-associated fibroblasts (CAFs) drives early recurrence in PC.
- Multiomics and spatial metabolomics identified elevated carnitine levels in CAFs and tumor cells in recurrent PC.
- Carnitine uptake activates the AMPK/PPARα/CPT1B pathway, enhancing fatty acid β-oxidation in cancer cells.
- Pharmacological inhibition of carnitine transport (e.g., meldonium, tetrahydropalmatine, quinidine) suppresses tumor growth and improves response to chemotherapy/immunotherapy.
- Targeting the carnitine shuttle system (CSS) may reduce recurrence and improve PC treatment outcomes.